A Pauci-Immune Synovial Pathotype Predicts Inadequate Response to TNF alpha-Blockade in Rheumatoid Arthritis Patients by Nerviani, A et al.
ORIGINAL RESEARCH
published: 05 May 2020
doi: 10.3389/fimmu.2020.00845
Frontiers in Immunology | www.frontiersin.org 1 May 2020 | Volume 11 | Article 845
Edited by:
Erminia Mariani,
University of Bologna, Italy
Reviewed by:
Maria I. Bokarewa,
University of Gothenburg, Sweden
Lucy R. Wedderburn,
University College London,
United Kingdom
*Correspondence:
Alessandra Nerviani
a.nerviani@qmul.ac.uk
Costantino Pitzalis
c.pitzalis@qmul.ac.uk
Specialty section:
This article was submitted to
Autoimmune and Autoinflammatory
Disorders,
a section of the journal
Frontiers in Immunology
Received: 16 December 2019
Accepted: 14 April 2020
Published: 05 May 2020
Citation:
Nerviani A, Di Cicco M, Mahto A,
Lliso-Ribera G, Rivellese F,
Thorborn G, Hands R, Bellan M,
Mauro D, Boutet M-A, Giorli G,
Lewis M, Kelly S, Bombardieri M,
Humby F and Pitzalis C (2020) A
Pauci-Immune Synovial Pathotype
Predicts Inadequate Response to
TNFα-Blockade in Rheumatoid
Arthritis Patients.
Front. Immunol. 11:845.
doi: 10.3389/fimmu.2020.00845
A Pauci-Immune Synovial Pathotype
Predicts Inadequate Response to
TNFα-Blockade in Rheumatoid
Arthritis Patients
Alessandra Nerviani*, Maria Di Cicco, Arti Mahto, Gloria Lliso-Ribera, Felice Rivellese,
Georgina Thorborn, Rebecca Hands, Mattia Bellan, Daniele Mauro, Marie-Astrid Boutet,
Giovanni Giorli, Myles Lewis, Stephen Kelly, Michele Bombardieri, Frances Humby and
Costantino Pitzalis*
Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London,
United Kingdom
Objectives: To assess whether the histopathological features of the synovium before
starting treatment with the TNFi certolizumab-pegol could predict clinical outcome and
examine the modulation of histopathology by treatment.
Methods: Thirty-seven RA patients fulfilling UK NICE guidelines for biologic therapy
were enrolled at Barts Health NHS trust and underwent synovial sampling of an
actively inflamed joint using ultrasound-guided needle biopsy before commencing
certolizumab-pegol and after 12-weeks. At 12-weeks, patients were categorized as
responders if they had a DAS28 fall >1.2. A minimum of 6 samples was collected for
histological analysis. Based on H&E and immunohistochemistry (IHC) staining for CD3 (T
cells), CD20 (B cells), CD138 (plasma cells), and CD68 (macrophages) patients were
categorized into three distinct synovial pathotypes (lympho-myeloid, diffuse-myeloid,
and pauci-immune).
Results: At baseline, as per inclusion criteria, DAS28 mean was 6.4 ± 0.9. 94.6%
of the synovial tissue was retrieved from the wrist or a metacarpophalangeal joint.
Histological pathotypes were distributed as follows: 58% lympho-myeloid, 19.4%
diffuse-myeloid, and 22.6% pauci-immune. Patients with a pauci-immune pathotype had
lower levels of CRP but higher VAS fatigue compared to lympho- and diffuse-myeloid.
Based on DAS28 fall >1.2, 67.6% of patients were deemed as responders and
32.4% as non-responders. However, by categorizing patients according to the baseline
synovial pathotype, we demonstrated that a significantly higher number of patients with
a lympho-myeloid and diffuse-myeloid pathotype in comparison with pauci-immune
pathotype [83.3% (15/18), 83.3 % (5/6) vs. 28.6% (2/7), p = 0.022) achieved clinical
response to certolizumab-pegol. Furthermore, we observed a significantly higher level
of post-treatment tender joint count and VAS scores for pain, fatigue and global
health in pauci-immune in comparison with lympho- and diffuse-myeloid patients but
no differences in the number of swollen joints, ESR and CRP. Finally, we confirmed
a significant fall in the number of CD68+ sublining macrophages post-treatment in
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responders and a correlation between the reduction in the CD20+ B-cells score and the
improvement in the DAS28 at 12-weeks.
Conclusions: The analysis of the synovial histopathologymay be a helpful tool to identify
among clinically indistinguishable patients those with lower probability of response
to TNFα-blockade.
Keywords: synovial tissue, anti-TNF, pathotype, rheumatoid arthritis, certolizumab-pegol
INTRODUCTION
Rheumatoid Arthritis (RA) is a chronic inflammatory
autoimmune disease characterized by persistent inflammation
of synovial tissue. If not adequately treated, it can lead to
progressive structural damage and subsequent disability (1).
Early diagnosis and the introduction of advanced therapeutics
for RA patients has resulted in substantial improvements in
clinical outcomes. However, irrespective of drug choice or
therapeutic target, response rates have remained stubbornly
fixed with approximately 60% of patients attaining a modest
20% improvement in disease activity (ACR20), while only
around 20% of patients achieving remission (2). In addition, the
mechanisms responsible for such variable response to therapy
are still unknown, and there are no biomarkers in regular clinical
use which are predictive of treatment response to individual
therapeutic agents (3). This is reflected in the most recent
EULAR recommendations for the management of RA (4) that
support the use of any of the available targeted therapeutics
following failure on conventional synthetic (cs) DMARDs,
implying a “trial and error” approach to treatment. Such an
approach leaves a huge unmet need and exposes patients to a
therapeutic lottery of drugs, which they may not respond to and
which may cause unnecessary adverse effects. Thus, there has
been considerable interest in trying to identify biomarkers of
treatment response in the diseased tissue (5), as the search in
peripheral blood has been largely unsuccessful (3). Heterogeneity
in the quantity and quality of synovial cellular infiltrate is well
recognized, and clustering of patients into three histological
categories (pathotypes) has recently been described in a large
early RA cohort as (i) lympho-myeloid, characterized by well-
organized B or plasma cell aggregates and rich in macrophages;
(ii) diffuse-myeloid, with predominant macrophages within
the sublining tissue and lacking B/plasma cell aggregates, and
(iii) pauci-immune, with scant infiltration of immune cells and
prevalence of resident fibroblasts (6). Importantly, synovial
molecular signatures have also been identified to associate
with each pathotype (7). Moreover, synovial pathotypes and
molecular signatures in the baseline biopsy are associated with
clinical phenotypes, clinical response to csDMARDs, radiologic
progression 12 months after the original biopsy (6, 7), and
predict future requirement for biologic therapy (8). These data
suggest that synovial biomarkers may be useful tools to stratify
patients’ response to biologic therapy. TNF inhibitors (TNFi)
are the most widely prescribed biologic drugs in RA, and thus
biomarkers of responses have been the most intensively sought.
However, whilst levels of TNFα in the peripheral blood have
repeatedly and consistently proven to be ineffective predictors
(9), synovial TNFα expression and factors such as the presence
of synovial B cell aggregates or specific gene signatures have been
variably associated with clinical outcomes (10–12).
In this study, therefore, capitalizing on the current
understanding of rheumatoid synovial histopathology, we aimed
to investigate whether specific histological features in synovium
prior to starting treatment with the TNFi certolizumab-pegol
could predict clinical outcome, and furthermore we examined
the modulation of histopathology by treatment.
METHODS
Patients
Thirty-seven RA patients [using the 1987 revised American
College of Rheumatology (ACR) classification criteria] (13)
fulfilling UK National Institute for Health and Care Excellence
(NICE) prescribing guidelines for biologic therapy (i.e., failure of
at least two csDMARDs and highly active disease demonstrated
by DAS28 > 5.1) (14) were enrolled in the study at Barts
Health NHS trust. Patients were excluded from the study if
daily oral prednisolone dose exceeded 10mg or if they have
previously received any biologic treatment, including non-anti-
TNF agents. Routine demographics including age, seropositivity
for rheumatoid factor and anti-citrullinated peptide antibodies,
disease duration, concomitant therapy and disease activity
assessment (DAS28) were performed at baseline. Patients
underwent synovial sampling of an actively inflamed joint
using ultrasound (US)—guided needle biopsy as previously
described (15) with collection of pre-biopsy US images.
US images of the biopsied joints were scored for both
synovial thickening (ST) and Power-Doppler (PD) using the
EULAR/OMERACTUS semi-quantitative synovitis score system
(0–3) (16). Patients were subsequently commenced on standard
treatment with subcutaneous certolizumab-pegol (400mg at 0–
2–4-weeks, then 200mg every other week). Twelve-weeks after
starting treatment, the number of swollen and tender joints
(28 joint count), patient visual analog score (VAS) for pain,
fatigue, global health and physician assessment of global health
were recorded along with Health Assessment Questionnaire
(HAQ). Patients were categorized as responders to therapy if a
DAS28 fall >1.2 was demonstrated between baseline and 12-
weeks, and non-responders if it did not. At 12-weeks, patients
were consented to undergo a second synovial biopsy of the
same joint sampled as at baseline. The study was approved
by the local ethics committee (Rec. No. 10/H0801/47) and
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written informed consent was obtained from all patients prior
to inclusion.
Histological Assessment of the Synovial
Tissue
A minimum of 6 samples was retrieved for histological analysis
from each biopsy procedure for subsequent paraffin embedding.
Following H&E staining of 3 µm-cut paraffin-embedded
sections, synovial tissue underwent immunohistochemical (IHC)
staining for CD3 (T cells), CD20 (B cells), CD138 (plasma
cells), and CD68 (macrophages), as previously described (17).
Synovial tissue was deemed as gradable if there was a visible lining
layer and/or presence of macrophages in the sublining. Two
independent scorers expert in synovial tissue histology quantified
the degree of the immune infiltrate using a semi-quantitative
score (0–4) as previously described (17). Subsequently, synovial
samples were categorized into three distinct synovial pathotypes
based on the following criteria: (i) Lympho-myeloid, if CD20+
B-cells score ≥ 2 and/or CD138+ plasma cells score > 2; (ii)
Diffuse-myeloid, if CD68+ sublining (SL) macrophages score ≥
2, CD20+ B-cells score ≤ 1 and CD138+ plasma cells score ≤ 2;
Pauci-immune, if CD68SL macrophages score < 2 and CD3+ T
cells score, CD20+ B cells score, and CD138+ plasma cells score
< 1 (6).
Statistical Analysis
Statistical analyses were performed using GraphPad Prism
version 8.2.1. A p < 0.05 was considered statistically significant.
Differences in continuous variables between two groups were
analyzed by T-test or Mann-Whitney U-test depending on
normality. Differences in variables between three or more groups
were assessed through one-way ANOVA or Kruskal-Wallis with
Dunn’s correction test. Wilcoxon matched-pairs rank test was
used to compare matched samples (e.g., pre- and post-treatment
variables in the same patient). Chi-squared or Fisher’s exact
test was applied to analyze the significance of the association
between categorical variables. Spearman’s correlation test was
used to assess the presence of significant correlations between
variables. Multiple logistic regression analysis was performed
with GraphPad Prism version 8.3.1. The binary clinical response
(based on DAS28 improvement ≥1.2) was used as the outcome.
The primary model was defined by the main effect of the
pathotype only. Additional models were adjusted by the inclusion
of several covariates such as age, gender, RF/CCP status and
baseline DAS28. The Sankey diagram in Figure 5 was plotted
using SankeyMATIC (http://sankeymatic.com).
RESULTS
Patients’ Characteristics
Patients’ baseline demographic and clinical features are
summarized in Table 1. Briefly, as expected in a population of
established RA, ∼80% of patients were female, and the average
age was 51.3 ± 11.7 years. About 70% of patients were either
rheumatoid factor (RF) or anti-cyclic citrullinated peptide (CCP)
antibody positive. As per the inclusion criteria of the study,
all patients had high disease activity (DAS28 6.4 ± 0.9). All
TABLE 1 | Baseline characteristics of the population included in the study
(n = 37).
Female % (n) 81% (30)
Age years (mean ± SD) 51.3 ± 11.7
Disease duration years (mean ± SD) 6.3 ± 5.8
Smoking status Previous % (n) 38.9% (14)
Current % (n) 22.2% (8)
RF+ % (n) 64.9% (24)
Anti-CCP+ % (n) 64.9% (24)
RF+ or Anti-CCP+ % (n) 70.3% (26)
ESR mm/h (mean ± SD) 31.1 ± 25.8
CRP mg/l mean (mean ± SD) 10.7 ± 20.2
TJ/28 (mean ± SD) 18 ± 8
SJ/28 (mean ± SD) 10 ± 4
VAS GH patient (mean ± SD) 82.1 ± 13.9
VAS GH physician (mean ± SD) 73.7 ± 15.2
VAS pain (mean ± SD) 67.8 ± 24.9
VAS tiredness (mean ± SD) 55.1 ± 25.2
HAQ (mean ± SD) 1.7 ± 0.7
DAS28 (mean ± SD) 6.4 ± 0.9
DMARDs MTX % (n) 24.3% (9)
LFN % (n) 5.4% (2)
MTX+HCQ % (n) 43.3% (16)
MTX+SSZ % (n) 24.3% (9)
MTX+SSZ+HCQ % (n) 2.7% (1)
Steroid treatment % (n) 35.1% (13)
Biopsied joint MCP % (n) 21.6% (8)
Elbow % (n) 2.7% (1)
Knee % (n) 2.7% (1)
Wrist % (n) 73% (27)
US BJ Synovial Thickening (mean ± SD) 2.4 ± 0.6
Power Doppler (mean ± SD) 1.6 ± 1
SD, Standard Deviation; n, number; RF, Rheumatoid Factor; CCP, Cyclic Citrullinated
Peptide; ESR, erythrocyte sedimentation rate; CRP, C-Reactive Protein; TJ, Tender Joints;
SJ, Swollen Joints; VAS, Visual Analog Scale (0-100); GH, Global Health; HAQ, Health
Assessment Questionnaire; DAS, Disease Activity Score; DMARDs, Disease Modifying
Anti-Rheumatic Drugs; MTX, methotrexate; LFN, leflunomide; HCQ, hydroxychloroquine;
SSZ, sulfasalazine; MCP, metacarpophalangeal; US BJ, Ultrasound Biopsied Joint.
patients were previously exposed to csDMARDs treatment but
were naïve to any biologics, and 35.1% of patients were on
concomitant steroid treatment (≤10mg per day) at the time of
the recruitment.
Histological Classification
A total of 37 patients were recruited to the study and underwent
a synovial biopsy at study entry (baseline). 28/37 patients
subsequently consented to a second synovial biopsy at 12-weeks
follow up (Figure 1A, Supplementary Figures 1, 2). 31/37
baseline synovial biopsies and 22/28 12-weeks repeated biopsies
yielded synovial tissue of sufficient quality for subsequent
histological analysis. Demographics and clinical features of
patients classified as “ungraded” (6 patients at baseline and
6 patients at 12-weeks) as well as those of patients who did
not undergo a repeated synovial biopsy post-treatment are
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summarized in Supplementary Tables 1, 2. At baseline, 58%
(18/31) were classified as lympho-myeloid, 19.4% (6/31) as
diffuse-myeloid, and 22.6% (7/31) as pauci-immune (Figure 1B).
Representative immunohistological images are shown in
Figure 1C, and the relative degree of immune cell infiltrate
per pathotype shown in Figure 1D. 94.6% of the synovial
tissue was retrieved from the wrist or a metacarpophalangeal
joint (Figure 1E). There was no difference in the pathotype
distribution among the various biopsy sites (Figure 1F).
Synovial Pathotypes and Baseline Clinical
Features
We next evaluated whether there were significant differences
in clinical parameters between patients stratified according
to baseline synovial pathotype (Table 2). We demonstrated
significantly lower levels of C-Reactive Protein (CRP)
(Figure 2A) but higher VAS fatigue score (Figure 2B) in
patients with a pauci-immune compared to lympho- and
diffuse-myeloid pathotypes. The US Power Doppler (USPD)
score of the biopsied joint was significantly higher in lympho-
myeloid patients, while the US synovial thickening (USST),
measured on gray-scale, was comparable among the three
pathotypes (Figures 2C,D). This suggests that although the total
proliferative cellular burden is the same across the pathotypes
there are differences in the nature of the inflammatory milieu
between the pathotypes, with increased vascularity observed in
the lympho-myeloid pathotype.
Baseline Synovial Histological Pathotypes
Associate With 12-Weeks Response to
Certolizumab-Pegol
Twelve-weeks after commencing certolizumab-pegol, 25/37
patients (67.6%) were classified as responders and 12/37
(32.4%) as non-responders based on a DAS28 fall >1.2
(1DAS28 response). We next stratified patients according
to synovial pathotype and evaluated whether there were
significant differences in clinical outcomes between groups. We
demonstrated that a significantly higher number of patients with
a lympho-myeloid and diffuse-myeloid pathotype in comparison
with pauci-immune pathotype [83.3% (15/18), 83.3 % (5/6) vs.
28.6% (2/7), Fisher test p = 0.022] were classified as responders
to therapy. A similar distribution was observed when EULAR
response criteria were applied: in this case, the rate of EULAR
non-responders was 16.7% in both lympho-myeloid and diffuse-
myeloid in comparison to 57.1% in pauci-immune patients
(Figure 3A). Consistent with this, we also observed a significant
fall in DAS28 score pre- and post-treatment in both the lympho-
myeloid and the diffuse-myeloid groups [6.4 ± 1 to 3.9 ± 1.5 (p
< 0.001) and 6.5 ± 0.8 to 3.2 ± 1.2 (p = 0.002) respectively]
but not in the pauci-immune group [6.7 ± 1 to 5.2 ± 1.6
(p = 0.06)] (Figure 3B). Using a dichotomic classification of
the pathotypes (lympho-myeloid and diffuse-myeloid vs. pauci-
immune) we observed a significantly lower response in the pauci-
immune group (Fisher test p = 0.01). The sensitivity of this
test as a predictor of response was 83% with a specificity of
71%; the positive predictive value was 90% and the negative
predictive value 56%. A logistic regression model including the
pathotype alone mirrored the results of the Fisher test (“Model
1” in Supplementary Table 3). The histological classification
remained significant when themodel was adjusted for age, gender
and RF/CCP status (“Model 2” in Supplementary Figure 2) as
well as in a larger model including also DAS28 at baseline
(“Model 3” in Supplementary Figure 2).
An Inadequate Response to
Certolizumab-Pegol in Patients
Categorized as Pauci-Immune Pathotype
Is Driven by Higher Levels of Tender Joint
Counts and Patient-Reported-Outcomes
As patients with a baseline pauci-immune histological pattern
were less likely to respond to certolizumab-pegol, we next
evaluated differences in individual components of clinical
response between pathotype groups at 12-weeks.
We demonstrated a significantly higher level of post-
treatment tender joint count and VAS scores for pain, fatigue
and global health in pauci-immune in comparison with lympho-
and diffuse-myeloid patients (Figure 4A): conversely, there
were no significant differences in the number of swollen
joints, ESR and CRP at 12-weeks post-treatment between
pathotype groups.
Furthermore, when evaluating changes in individual
components of the DAS28 score between baseline and 12-
weeks follow up we saw the most significant falls in ESR,
tender joint count, swollen joint count and VAS global
health in the lympho-myeloid group. In the pauci-immune
group only ESR level and swollen joint count significantly
decreased after treatment (Figure 4B). Overall, this data
suggests that while anti-TNF therapy is highly effective
in the “inflammatory” pathotypes, it is less effective at
reducing joint tenderness, pain and overall health scores in
the pauci-immune patients.
Clinical Response at 12-Weeks Associates
With a Reduction in the Number of
Sublining Macrophages and Size of
Synovial B Cells Aggregates
In order to evaluate the changes in synovial histopathology
between baseline and 12-weeks, we focused on a subset of 17
patients who had gradable synovial tissue at both time-points
(Supplementary Table 1). At 12-weeks, of these 17 patients,
47% (8/17) were classified as lympho-myeloid, 17.7% (3/17) as
diffuse-myeloid and 35.3% (6/17) as pauci-immune pathotype.
Overall, 70.6% patients maintained the same pathotype as
baseline, 23.5% changed to a less inflammatory and 5.9% to
a more inflammatory histological patter. We then evaluated
the change in synovial pathotype per patient between baseline
and 12-weeks. We observed that, following anti-TNF treatment,
the percentage of lympho-myeloid decreased from 58 to
47% while the number of pauci-immune patients increased
from 22.6 to 35.3%. Furthermore, in the absence of B cell
aggregates at baseline, patients did not develop B cells and/or
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FIGURE 1 | (A–F) Design of the study and histological characterization of the synovial tissue. (A) Timeline of the study, which included a baseline US-guided needle
synovial biopsy at week 0 (37 patients) and a second biopsy of the same joint after 12-weeks of treatment with certolizumab-pegol (28 patients). At the top,
(Continued)
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FIGURE 1 | representative gray-scale transverse section of an US-guided wrist biopsy showing the needle entering the joint space underneath the IV extensor tendons
compartment. (B) Distribution (%) of synovial pathotypes at baseline. (C) Representative images of immunohistochemistry staining of synovial tissue for immune cells
markers and classification in three pathotypes: lympho-myeloid, diffuse-myeloid and pauci-immune. Original magnification 4x. (D) Heatmap showing the degree of
infiltration of immune cells (CD20, B-cells; CD138, plasma cells; CD3, T-cells; CD68L, macrophages of the lining; CD68SL, macrophages of the sublining) in each
pathotype. (E) Distribution (%) of biopsied joints. (F) Histological pathotype according to synovial biopsy site. MCP, metacarpophalangeal. Fisher’s test: not significant.
TABLE 2 | Analysis of baseline features by pathotype.
Lymphoid-Myeloid
(58%, n = 18)
Diffuse-Myeloid
(19.4%, n = 6)
Pauci-Immune
(22.6%, n = 7)
p-value
Female % (n) 77.8% (14) 100% (6) 100% (7) 0.356a
Age years (mean ± SD) 50.4 ± 10.8 47.5 ± 17.6 54.7 ± 11.8 0.577b
Disease duration years (mean ± SD) 5.05 ± 3.7 4.8 ± 5.3 5.1 ± 6.3 0.992b
RF+ % (n) 72.2% (13) 50% (2) 71.4% (5) 0.588a
ACPA + % (n) 72.2% (13) 50% (3) 57.1% (4) 0.595a
RF or ACPA + % (n) 77.8% (14) 50% (3) 71.4% (5) 0.418a
ESR mm/h (mean ± SD) 30.53 ± 24.74 54.5 ± 33.2 25.4 ± 21.2 0.107b
ESR mm/h (mean ± SD) 30.53 ± 24.74 54.5 ± 33.2 25.4 ± 21.2 0.107b
CRP mg/l (mean ± SD) 8.9 ± 6.6 30.6 ± 46.2 2.2 ± 3.9 *0.020b
TJ/28 (mean ± SD) 17.4 ± 8.7 13 ± 6.4 22.6 ± 4.3 0.087b
SJ/28 (mean ± SD) 10.5 ± 5 8.7 ± 2.7 9.3 ± 4.9 0.675b
VAS GH pt (mean ± SD) 83.5 ± 13.6 72.7 ± 16.4 86.3 ± 16.3 0.230b
VAS GH phys (mean ± SD) 79.9 ± 12.6 65.2 ± 22 71 ± 12.5 0.112b
VAS pain (mean ± SD) 63.9 ± 27.9 54.7 ± 25.2 87.2 ± 16.6 0.101b
VAS tiredness (mean ± SD) 47.8 ± 22.6 46.7 ± 29 76.5 ± 17.5 *0.038b
HAQ (mean ± SD) 1.7 ± 0.7 1.4 ± 0.8 2 ± 0.8 0.451b
DAS28 (mean ± SD) 6.4 ± 1 6.5 ± 0.8 6.7 ± 1 0.787b
Steroid % (n) 27.8% (5) 50% (3) 42.9% (3) 0.595a
USST biopsied joint 2.6 ± 0.6 2 ± 0.6 2.4 ± 0.5 0.112b
USPD biopsied joint 2.1 ± 1 1 ± 0.9 1.1 ± 0.7 *0.023b
Steroid treatment % (n) 27.8% (5) 50% (3) 42.8 (3) 0.595a
DMARDs MTX % (n) 33.3% (6) 0% (0) 14.3% (1) c >0.999
LFN % (n) 5.55% (1) 0% (0) 14.3% (1)
MTX+HCQ % (n) 27.8% (5) 66.7% (4) 57.1% (4)
MTX+SSZ % (n) 27.8% (5) 33.3% (2) 14.3% (1)
MTX+SSZ+HCQ
% (n)
5.55% (1) 0% (0) 0% (0)
Baseline characteristics were compared by Fisher’s exact testa or Kruskal-Wallis with post-hoc Dunn’s testb as appropriate. cDMARDs treatment distribution was analyzed as
monotherapy vs. multiple DMARDs in lympho/diffuse-myeloid vs. pauci-immune. *p < 0.05 was considered statistically significant. SD, Standard Deviation; n, number; RF, Rheumatoid
Factor; CCP, Cyclic Citrullinated Peptide; ESR, erythrocyte sedimentation rate; CRP, C-Reactive Protein; TJ, Tender Joints; SJ, Swollen Joints; VAS, Visual Analog Scale (0–100); GH,
Global Health; HAQ, Health Assessment Questionnaire; DAS, Disease Activity Score; DMARDs, Disease Modifying Anti-Rheumatic Drugs; MTX, methotrexate; LFN, leflunomide; HCQ,
hydroxychloroquine; SSZ, sulfasalazine; MCP, metacarpophalangeal; USST, Ultrasound Synovial Thickening; USPD, Ultrasound Power-Doppler.
plasma cells post-treatment, and so there was no transition
to the most inflammatory pathotype (lympho-myeloid) at 12-
weeks (Figure 5A).
Next, we assessed the change in CD68+ sublining
macrophages between baseline and 12-weeks in responders
and non-responders to certolizumab-pegol and observed
a significant fall of this cell subset in responder patients
(Figure 5B). We also confirmed a significant correlation between
change in CD68+ sublining macrophages and change in DAS28
score between baseline and 12-weeks (Figure 5C). Similarly,
we evaluated whether modulation of synovial CD20+ B cells at
12-weeks was related to clinical response. We analyzed patients
with a lympho-myeloid pathotype at baseline who had a suitable
synovial tissue for histological characterization post-treatment
(11 patients). Only one patient was deemed as non-responder;
therefore, in terms of clinical response, we did not detect any
significant difference between patients with persistence (8/11,
from baseline lympho-myeloid to lympho-myeloid at 12-weeks)
or complete resolution of CD20+ B-cells aggregates (3/11, from
baseline lympho-myeloid to diffuse-myeloid or pauci-immune
at 12-weeks). We next stratified responders patients into those
with a change in CD20 scores of ≥ 0 between baseline and
12-weeks, meaning same or higher B-cell score post-treatment,
and those with a change of <0 (indicating a lower B-cell score
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FIGURE 2 | (A–D) Violin plots showing differences in CRP (A), VAS fatigue (0–100) (B), ultrasound (US) Power-Doppler (PD) score (0–3) (C) and US synovial
thickening (ST) score measured in gray-scale (0–3) (D) of the biopsied joints between pathotype groups. Median and interquartile ranges are represented by thick and
thin dotted lines, respectively. **p < 0.01, *p < 0.05, Kruskal-Wallis with post-hoc multiple comparison on 31 patients.
at 12-weeks); then, we evaluated the mean change in DAS28
scores between the two groups. Our results suggested that
patients with a reduction in the CD20+ B-cells score after
treatment had a significantly greater improvement of the disease
activity score at 12-weeks (Figure 5D). We also assessed the
relationship between absolute change in DAS28 and differences
in the CD20+ B-cell scores between baseline and 12-weeks and
showed a significant correlation (r = 0.66, p < 0.05), suggesting
that clinical improvement is associated with falls in CD20
scores and clinical worsening with increased scores (Figure 5E).
These data demonstrate that depletion of synovial sublining
macrophages and B cells are important factors in responsiveness
to anti-TNF treatment.
DISCUSSION
Despite the considerable improvement in outcomes for RA
patients since the introduction of TNFi therapy, clinicians are
still unable to reliably identify patients most likely to respond
to specific therapies, which remains a huge unmet clinical need.
The identification of peripheral blood biomarkers of clinical
response to TNFi therapy has been largely unsuccessful (3) and
so focus has shifted to the examination of the primary site of
inflammation in RA, i.e. synovial tissue (5). Early studies on
this topic recognized the heterogeneity of rheumatoid synovitis
and the presence of high- and low-inflammation synovial tissue,
with the former being associated with higher disease activity and
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FIGURE 3 | (A) Table summarizing clinical response rates by pathotypes to certolizumab-pegol at 12-weeks. 1DAS28 was calculated by subtracting the
baseline-DAS28 value from the 12-weeks-DAS28; DAS28 fall > 1.2 defined “responders.” Distribution of response rates was tested by Fisher’s exact test while
differences in 1DAS28 by Kruskal-Wallis with Dunn’s test. SD, standard deviation. (B) Comparison of pre- (pre-TH) and post-treatment (post-TH) DAS28 by
pathotype. ***p < 0.001, **p < 0.01, Kruskal-Wallis with post-hoc Dunn’s multiple comparison test on 31 patients. Red dotted line represents DAS28 5.1 (“high
disease activity”); green dotted line represents DAS28 3.2 (“low disease activity”).
systemicmarkers of inflammation (18). More recently, numerous
studies defining the cellular and molecular composition of
the rheumatoid synovium both at single-cell (19, 20) and
whole-tissue (6, 7) level have confirmed the heterogeneity and
complexity of the tissue in its diseased state as well as its
association with clinical phenotypes.
Here, we characterized for the first time the baseline features
of the synovial tissue of a homogeneous group of 37 inadequate
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FIGURE 4 | (A) Table summarizing the comparison by pathotype of the patients’ clinical features at 12-weeks post-treatment (*Kruskal-Wallis with Dunn’s correction).
Significantly different variables are in bold. (B) Comparison of pre- (pre-TH) and post-treatment (post-TH) individual parameters of the DAS28 by pathotype. p values
were calculated with Wilcoxon
(Continued)
Frontiers in Immunology | www.frontiersin.org 9 May 2020 | Volume 11 | Article 845
Nerviani et al. RA Pathotypes Predict Anti-TNF Response
FIGURE 4 | matched-pairs rank test (31 patients); ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05. Green dots and line: “responders”; red dots and lines:
“non-responders”. SD, Standard Deviation; ESR, erythrocyte sedimentation rate; CRP, C- Reactive Protein; TJ, Tender Joints; SJ, Swollen Joints; VAS, Visual Analog
Scale (0–100); GH, Global Health; pt, patient; phy, physician; tir, tiredness; HAQ, Health Assessment Questionnaire.
responders to csDMARDs by applying a histologic algorithm
previously validated in a different and independent large
cohort of early RA patients and evaluated whether synovial
histological characteristics prior-to-treatment correlated with
clinical response to the TNFα inhibitor certolizumab-pegol.
Firstly, we confirmed the presence of all three synovial
pathotypes as described early in the disease and prior to
any treatment intervention (6, 7). These include a pauci-
immune pathotype, which, despite the absence of infiltrating
inflammatory cells, can be detected in RA patients with active
disease fulfilling UK NICE criteria for starting biologic treatment
(DAS28 > 5.1). The relative prevalence of the lympho-myeloid
pathotypes in this RA cohort with established, more longstanding
disease was higher than in early, untreated RA [58% vs. 39%
(6)]. This is in line with the recent observation in early RA that
patients characterized by a lympho-myeloid pathotype at disease
onset are more likely to progress in terms of increasing joint
damage as assessed on x-ray and are subsequently more likely to
require biologic therapy at 12 months follow up (8).
The relationship between the baseline histological
characteristics and the clinical response was assessed at 12-
weeks by the change in the DAS28 pre- and post-treatment, since
improvement in DAS28 < 1.2 at 12-weeks has been shown to
be the best predictor of inadequate response at 1 year (21, 22).
Overall, 67.6% of the treated patients improved their baseline
DAS28 of ≥1.2 and were deemed as responders, aligned with
the standard rates of response to TNFα inhibitors in clinical
trials (23). However, when patients were categorized according
to the baseline histological pattern, the rate of responders
enriched from 67.6% up to 83.3% in both the lympho-myeloid
and diffuse-myeloid pathotypes; conversely, a pauci-immune
synovitis, i.e. scanty synovial inflammatory infiltrate, associated
with a significantly lower rate of response (28.6%), impaired
reduction of the DAS28 from pre- to post-treatment and higher
absolute values of DAS28 at 12-weeks. Notably, and in line with
these results, a pauci-immune-fibroblast signature in synovium
of treatment-naïve patients (independent from the cohort
included in this manuscript) has been found to be associated
with resistance to csDMARDs in early-RA (7).
Moreover, by dissecting the post-treatment DAS28 into its
individual variables, we demonstrated that the main drivers of
the inadequate response in the pauci-immune patients at 12-
weeks were the high number of tender joints and the patient
global health VAS score whereas ESR and swollen joint count
were comparable among the three pathotypes. All the patient-
reported-outcomes recorded at 12-weeks, including fatigue and
pain, were consistently higher in pauci-immune patients. Thus,
although anti-TNF therapy reduced ESR and CRP in pauci-
immune patients, it was less effective at reducing joint tenderness
and pain scores in pauci-immune patients compared to the other
pathotypes. Interestingly, the dissociation of pain scores from
markers of inflammation has been recently described in a group
of patients bearing a molecularly-defined “low inflammatory”
subtype of synovitis characterized by the up-regulation of
neurogenesis pathways and TGF-β (24). Thus, altogether, these
data support the notion of a distinct “hyperalgesic” clinical
phenotype linked to the pauci-immune pathotype. The role
played by the synovial histopathology in predicting the response
to TNFi has been long debated, particularly, because of the
discordant findings coming from various observational studies.
To date, chief attention has been given to lymphocytic structures
within the synovial tissue. Their presence has been associated
with the achievement of clinical response in some (25), though,
not all studies (26); alternatively, it has been proposed that
the disruption of the lymphoid follicles is instead critical for
the success of the treatment (26), hence leaving the question
substantially unanswered. Similarly, molecular analysis of the
synovial tissue showed that, in some cases, an up-regulation of
inflammation-related andmyeloid genes characterized responder
patients (11, 12) whereas, in others, high synovial content of pro-
inflammatory IL7-receptor and IL-18 predicted the absence of
response to TNFα blockade (27).
Here, our results suggest that both the baseline high-
inflammatory pathotypes lympho-myeloid and diffuse-myeloid,
differentiated by the presence/absence of B and/or plasma
cell aggregates but both sharing a substantial infiltration by
macrophages, had significantly better chances to respond to
TNFα inhibition by certolizumab-pegol than patients with a
pauci-immune pathotype. Our findings are in line with previous
data demonstrating that a myeloid gene signature (12) as well
as higher levels of synovial TNFα (28) pre-treatment predict
enhanced response to TNFα-blockade. Conversely, the virtual
absence of immune cells seems favoring the absence of clinical
response, which may be potentially driven by other pathways
including maladaptive pain response.
Finding that clinical response to certolizumab-pegol
is significantly associated with a fall in CD68+ sublining
macrophages is in line with the well-established literature
recognizing the decrease in synovial macrophages as a validated
biomarker of the clinical efficacy of various therapeutic
interventions (29, 30). Several studies involving the use of anti-
TNFα agents, including our previous observations (31), have
already shown that the reduction in the number of sublining
macrophages from baseline, also at early time-points after
starting the treatment, associated with clinical response in RA
(32, 33); we have here further confirmed this evidence. This early
reduction in sublining CD68-positive cells in future responders
to TNFi has also been mirrored in the peripheral blood by the
change in myeloid-related-protein (MRP) 8/14 (34).
We also showed that if B cells and plasma cells are absent
at baseline, as occurs in the diffuse-myeloid and pauci-immune
pathotypes, there is no evolution toward a lympho-myeloid
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FIGURE 5 | (A) Sankey diagram representing the shift of pathotypes from pre- to post-treatment of the 17 patients who had gradable tissue both at baseline and
12-weeks. (B) Comparison of the delta (1) CD68 sublining (SL) score between responders and non-responders. 1CD68SL is the difference in the CD68SL
(Continued)
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FIGURE 5 | semi-quantitative score (0–4) between post- and pre-treatment. Mean and standard deviation shown. **p < 0.01 (Mann-Whitney). (C) Correlation plot
showing 1DAS28[12−weeks−baseline] and 1CD68SL[12−weeks−baseline]; r Spearman coefficient of correlation, **p < 0.01. (D) Comparison of 1DAS28 between patients
with same/higher (1CD20≥0) or reduced CD20+ B-cells score (1CD20 < 0) post treatment. **p < 0.01 (Mann-Whitney, mean and standard deviation shown). (E)
Correlation plot showing 1DAS28[12−weeks−baseline] and 1CD20[12−weeks−baseline]. r Spearman coefficient of correlation, **p < 0.01. Only responder lympho-myeloid
patients were analyzed in (D,E) (10 patients). (B–E) Individual dots are color-coded by pathotype (blue, lympho-myeloid; red, diffuse-myeloid; orange, pauci-immune).
pathotype after treatment, in agreement with early works
demonstrating a reduced synovial cellular infiltration upon
treatment with infliximab (35). We observed that a decrease
in the CD20+ B-cell score post-treatment associated with
improvement in theDAS28. Thus, depletion of synovial sublining
macrophages and B cells are important factors for effective
response to anti-TNF treatment. Overall, these data suggest
that a shift toward a less inflammatory synovial environment
after treatment associates with greater improvement in clinical
disease activity, in line with similar observations in early RA
patients following csDMARD therapy (7). Because certolizumab-
pegol exerts its action by dampening inflammation through
inhibition of TNFα, it is reasonable that it does not adequately
target the pauci-immune pathotype. Hence, the development of
novel therapeutics targeting the fibroblastic synovial component
and aberrant nociceptive pathways may be required in the
pauci-immune patient cohort and support the notion that a
personalized medicine, biomarker driven approach to treating
patients with arthritis is required.
In conclusion, we have demonstrated that the analysis of the
synovial histopathology may be a valuable tool to discern among
clinically indistinguishable patients those with less chance of
responding to TNFα-blockade, and additional research efforts are
required to properly target the pauci-immune pathotype.
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